Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)




Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).

The Common Shares were sold at a price of USD$7.50 per Common Share.

Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis).

Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.

This press release has been issued in order to comply with applicable securities legislation.

CONTACT: For further information: 
Anthony J. Buffalano III
Southpoint Capital Advisors LP
1114 Avenue of the Americas, 22nd Floor
New York, NY 10036
Phone: (212) 692-6356

Outlook Therapeutics Announces New Employment Inducement Grants




Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees.

The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retinal diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD (wet age-related macular degeneration). Outlook Therapeutics commenced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the treatment of wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

Best Peptides for Weight Loss 2026: Industry Analysis Examines Compounded GLP-1 Telehealth Access and Pricing Transparency




Best Peptides for Weight Loss 2026: Industry Analysis Examines Compounded GLP-1 Telehealth Access and Pricing Transparency

Sprout Health Serves as Case Study for Provider Model Structure, Program Costs, and FDA-vs-Compounded Disclosure Standards

Orlando, Dec. 26, 2025 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and is not medical advice. “Best” in this context refers to an industry analysis framework examining verification factors, service-model transparency, provider model structure, and disclosure quality—not clinical superiority or guaranteed outcomes. Compounded GLP-1 medications are prepared by licensed U.S. pharmacies and are not FDA-approved as finished products. They have not been reviewed or approved by the FDA for weight loss or weight management. FDA-approved branded medications such as Ozempic (semaglutide) and Wegovy (semaglutide) exist separately—Ozempic is approved for type 2 diabetes and may be prescribed off-label for weight management; Wegovy is FDA-approved for chronic weight management. The branded medication Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes; Zepbound (tirzepatide) is FDA-approved for weight management. Evaluation by a licensed clinician is required for prescription medications, and prescription approval is not guaranteed. Always consult a qualified healthcare professional before starting prescription treatments. This article contains affiliate links; if you purchase through these links, a commission may be earned at no additional cost to you.

As millions of Americans prepare New Year weight loss resolutions for 2026, consumer interest in “best peptides for weight loss” remains elevated, reflecting ongoing demand for prescription GLP-1 medications as part of medically supervised weight management. This industry analysis examines how telehealth platforms are structuring access to compounded semaglutide and tirzepatide, with Sprout Health Weight Loss serving as a representative case study based on publicly available disclosures from its platform.

For those researching peptides for fat loss or prescription weight loss peptides heading into 2026, understanding what telehealth platforms actually offer—and what they don’t guarantee—is essential before making any decisions.

Important Regulatory Context: The FDA has increased scrutiny of compounded GLP-1 telehealth marketing across the industry in recent years. According to FDA guidance, compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before marketing. The FDA has also warned about potential dosing errors with compounded GLP-1 products and has noted reports of compounders using salt forms (such as semaglutide sodium or semaglutide acetate) and adding other ingredients where safety and effectiveness have not been established. Consumers should verify that any platform they consider clearly distinguishes between FDA-approved branded medications and compounded formulations, and should review current disclosures before proceeding with any program.

Understanding the Search Intent: What “Best Peptides for Weight Loss” Actually Means

When people search for “best peptides for weight loss,” they’re typically at a specific point in their research journey. They’ve likely seen advertisements for GLP-1 medications on social media, heard about dramatic weight loss results from friends or news coverage, and are now looking to understand their options for accessing these prescription weight loss peptides.

The phrase “peptides for weight loss” in this context primarily refers to GLP-1 receptor agonists—a class of medications that includes semaglutide and tirzepatide. These compounds work by mimicking natural hormones that regulate appetite and blood sugar, and clinical research has documented significant weight loss outcomes in controlled trial settings.

What the research shows about GLP-1 medications:

According to a study published in the New England Journal of Medicine (STEP-1 trial), participants receiving once-weekly semaglutide 2.4 mg plus lifestyle intervention experienced a mean weight loss of 14.9% from baseline over 68 weeks, compared with 2.4% for placebo plus lifestyle intervention. In the SURMOUNT-1 trial, also published in NEJM, participants receiving tirzepatide achieved weight reductions ranging from 16.0% to 22.5% depending on dose over 72 weeks.

Critical clarification: These results come from clinical trials of FDA-approved branded medications conducted under controlled conditions with specific patient populations. Compounded versions of semaglutide and tirzepatide—such as those available through telehealth platforms—have not undergone the same FDA approval process. Individual results with any GLP-1 medication, whether branded or compounded, vary based on numerous factors including adherence, lifestyle modifications, baseline health status, and individual physiology.

The Telehealth Platform Model: Three-Entity Structure Explained

Understanding how GLP-1 telehealth platforms operate is essential before considering whether this access model aligns with your needs. According to disclosures published by Sprout Health, the company functions as a telehealth platform—not a healthcare provider—that connects users with independent licensed clinicians and partner compounding pharmacies.

Entity 1: The Platform

According to the company’s terms of use, Sprout Health Partners LLC operates the technology platform at joinsprouthealth.com. The platform provides the intake process, customer support, subscription management, and coordination between patients, providers, and pharmacies. The platform itself does not prescribe medications or make clinical decisions.

Entity 2: Independent Licensed Medical Providers

The company works with licensed clinicians through MD Integrations (MDI), a physician network. According to the company’s disclosures, these independent providers review patient medical questionnaires, conduct evaluations (which may include synchronous video visits in states that require them), and determine whether GLP-1 prescriptions are appropriate based on individual health factors.

Prescription approval is not guaranteed. The licensed clinician makes this determination independently based on your specific medical history, current health status, and treatment goals.

Entity 3: Partner Compounding Pharmacies

If a prescription is written, it is filled by one of the platform’s partner compounding pharmacies, which the company identifies as Foothills Pharmacy and Promise Pharmacy. According to the company, these pharmacies prepare compounded medications under applicable federal and state compounding rules.

This three-entity structure—platform, providers, pharmacy—ensures appropriate separation between technology coordination, clinical decision-making, and medication dispensing. This structure is standard across compounded semaglutide telehealth platforms operating in this category.

What Compounded GLP-1 Medications Are—And What They Are Not

Before proceeding with any GLP-1 telehealth program, understanding the distinction between FDA-approved branded medications and compounded versions is critical for anyone researching peptides for fat loss options.

FDA-approved branded GLP-1 medications include:

Ozempic and Wegovy (semaglutide by Novo Nordisk) and Mounjaro and Zepbound (tirzepatide by Eli Lilly) have undergone extensive clinical trials and FDA review processes. These branded medications have demonstrated safety and efficacy for their approved indications under controlled conditions.

Compounded medications are different:

According to FDA guidance, compounded drug products are not FDA-approved. They are prepared by licensed pharmacies based on individual prescriptions but have not been individually reviewed by the FDA for safety, effectiveness, or quality. The FDA states that compounded drugs are “not reviewed by FDA prior to marketing and are not FDA-approved.”

What this means for consumers:

When accessing compounded semaglutide or tirzepatide through telehealth platforms, you are receiving a medication that contains the same active ingredient as FDA-approved products but is prepared differently and has not undergone FDA approval as a finished product. The evaluating clinician determines whether this option is appropriate based on your individual health factors.

Pricing Structure: What Platform Disclosures Indicate

According to pricing disclosures published on the Sprout Health platform, the program structure is as follows:

Compounded Semaglutide: As disclosed on the company’s website, the program costs $249/month. This includes evaluations by a licensed medical provider, follow-up appointments, messaging access to clinicians, a 4-week supply of medication (if prescribed), and shipping.

Compounded Tirzepatide: As disclosed on the company’s website, the program costs $299/month with the same inclusions as the semaglutide program.

Promotional Offer: The company advertises $50 off the first month with code FIRST50, bringing initial costs to $199 for semaglutide and $249 for tirzepatide.

Important pricing notes from the company’s disclosures:

According to the company, the initial medication price is honored even if dosages increase over time. The platform operates on a month-to-month basis with no long-term contracts. According to the terms of use, users can cancel at any time through the “Cancel Plan” option in the Profile tab of their customer portal, with cancellation taking effect at the end of the current subscription period. According to the company’s refund policy, prescriptions are non-refundable after processing; refunds are only available before medication has been processed by the pharmacy.

Insurance: The company explicitly states that Sprout Health does not accept or bill insurance. Some HSA/FSA plans may reimburse qualifying prescription expenses; verify eligibility with your specific plan administrator.

Verify current pricing, promotional offers, and program terms directly with the platform, as these details may change.

The Evaluation Process: What to Expect

According to publicly available information from Sprout Health, the process works as follows:

Step 1: Pre-Qualification Quiz

The company provides a brief online assessment asking about age, weight loss goals, medical history, and current health status. This determines initial eligibility for the program.

Step 2: Plan Purchase and Medical Questionnaire

If pre-qualified, users purchase their selected plan and complete a detailed medical questionnaire. According to the company, this questionnaire must be completed promptly to avoid processing delays.

Step 3: Provider Review

A licensed clinician reviews the medical questionnaire and determines whether GLP-1 medication is appropriate. According to the company, if found unqualified, the order is cancelled and refunded. The company states that some states require synchronous (video) visits—according to their disclosures, these states include AR, CO, ID, IL, IN, MD, MO, MT, NE, NY, OK, SD, VT, VA, and WI.

Step 4: Prescription and Shipping

If prescribed, the prescription is sent to a partner pharmacy. According to the company, prescriptions are typically sent within two business days. Delivery is typically 3-5 business days after the prescription is approved and processed, with total time from prescription to delivery often 5-7 business days.

Geographic Availability:

According to the company’s terms of service, the platform currently serves patients in: AK, AZ, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, ME, MD, MA, MI, MN, MO, MT, NE, NV, NH, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, and WY.

States NOT currently served: AL, AR, MS, LA, CA, ND.

Understanding GLP-1 Medications: How They Work

GLP-1 stands for glucagon-like peptide-1. GLP-1 receptor agonists are a class of medications that mimic natural hormones involved in appetite regulation and blood sugar control. Some GLP-1 medications, like tirzepatide, also act on GIP (glucose-dependent insulinotropic polypeptide) receptors, which is why tirzepatide is sometimes called a “dual agonist.”

Mechanism of action (based on published research):

According to research published in peer-reviewed journals, GLP-1 receptor agonists work through several mechanisms:

They slow gastric emptying, which can increase feelings of fullness after meals. They act on brain regions involved in appetite regulation, potentially reducing hunger signals. They improve glycemic control by enhancing insulin secretion in response to food intake.

What published clinical research shows:

The STEP-1 trial (semaglutide, published in NEJM 2021) demonstrated that participants with obesity or overweight without diabetes who received semaglutide 2.4 mg weekly plus lifestyle intervention experienced mean weight loss of 14.9% over 68 weeks.

The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% (5mg), 21.4% (10mg), and 22.5% (15mg) over 72 weeks.

This is ingredient-level research. These studies evaluated FDA-approved branded medications under controlled clinical trial conditions. Compounded versions of these medications have not been studied in the same manner. Individual results with any GLP-1 medication vary significantly. These individual research findings do not guarantee outcomes with compounded products.

Who GLP-1 Therapy May Be Appropriate For (Self-Assessment Framework)

Rather than presenting testimonials—which can reflect self-selection bias and individual experiences that may not be typical—this framework helps you evaluate whether pursuing a GLP-1 consultation heading into 2026 may align with your situation.

GLP-1 Therapy Through Telehealth Platforms May Align Well With People Who:

Have a BMI of 30 or greater, or 27 or greater with weight-related health conditions: This generally aligns with clinical guidelines for considering medical weight management interventions alongside lifestyle modifications.

Have not achieved desired results with diet and exercise alone: GLP-1 medications are studied as adjuncts to lifestyle intervention, not replacements for healthy eating and physical activity.

Are comfortable with the telehealth model: This includes completing online questionnaires, potentially having video consultations, and managing prescriptions remotely.

Can commit to ongoing subscription costs: At price points in the $249-$299/month range (based on current platform disclosures), the financial commitment is significant and ongoing.

Understand that results vary: Not everyone responds to GLP-1 medications, and individual weight loss outcomes differ based on numerous factors.

Are located in a state where services are available: Verify your state is included in any platform’s service area before proceeding.

Other Options May Be Preferable For People Who:

Prefer FDA-approved branded medications: Those seeking medications that have undergone FDA approval processes may prefer to work with in-person providers who can prescribe branded Wegovy, Zepbound, or other approved products.

Have certain medical contraindications: GLP-1 medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other contraindications may apply based on individual health factors.

Are located in states not currently served: If you’re in a state where a platform doesn’t operate, you would need to explore other options.

Prefer in-person medical care: Those who value face-to-face interactions with healthcare providers may find traditional medical settings more appropriate.

Questions to Ask Yourself:

Before pursuing any prescription weight loss peptides program, consider:

Have I discussed weight management options with my primary care provider? Do I understand the difference between FDA-approved branded medications and compounded formulations? Am I prepared for potential side effects, which can include nausea, vomiting, diarrhea, and other gastrointestinal symptoms? Can I sustain the monthly cost for the duration needed to achieve and maintain results? Am I committed to the lifestyle modifications that are essential components of any successful weight management approach?

Your answers help determine whether this type of program aligns with your specific situation and goals.

Potential Side Effects and Safety Considerations

According to general medical literature, GLP-1 medications may cause various side effects:

Common side effects may include:

Nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. These gastrointestinal effects are among the most frequently reported and may occur especially during dose escalation.

Less common but more serious potential effects may include:

Pancreatitis, gallbladder issues, kidney problems, and severe gastrointestinal symptoms. GLP-1 medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Always discuss your full medical history and any medications you take with your licensed provider before starting therapy. This safety overview is not exhaustive and does not replace full prescribing information. Always review complete safety information with your prescribing clinician and pharmacist.

Frequently Asked Questions

What are the best peptides for weight loss in 2026?

According to clinical research, the most effective peptide-based weight loss medications are GLP-1 receptor agonists, specifically semaglutide and tirzepatide. The STEP-1 trial demonstrated mean weight loss of 14.9% with semaglutide over 68 weeks, while the SURMOUNT-1 trial showed tirzepatide achieving 16-22.5% weight reduction over 72 weeks. These results are from FDA-approved branded medications studied under controlled conditions. Compounded versions of these peptides, available through telehealth platforms, have not undergone the same FDA approval process.

How much does compounded semaglutide typically cost through telehealth platforms?

Pricing varies by platform. According to disclosures from Sprout Health, compounded semaglutide costs $249/month and compounded tirzepatide costs $299/month through that platform. Promotional discounts may be available. Always verify current pricing directly with any platform before purchasing, as terms are subject to change.

Are compounded GLP-1 medications FDA-approved?

No. Compounded semaglutide and tirzepatide are not FDA-approved as finished products. They are prepared by licensed pharmacies based on individual prescriptions but have not been individually reviewed by the FDA for safety, effectiveness, or quality. FDA-approved branded medications include Wegovy and Ozempic (semaglutide) and Zepbound and Mounjaro (tirzepatide).

How long does it take to see results with GLP-1 medications?

According to clinical trial data for FDA-approved branded medications, measurable weight loss typically begins within the first few weeks, with more significant results appearing over months of consistent use. The STEP-1 trial measured outcomes at 68 weeks; the SURMOUNT-1 trial at 72 weeks. Individual timelines vary significantly. Compounded versions have not been studied in the same controlled manner, so these timelines may not apply.

What should I verify before choosing a GLP-1 telehealth platform?

Before selecting any platform, verify that disclosures clearly distinguish between FDA-approved branded medications and compounded formulations, that the three-entity structure (platform, providers, pharmacy) is transparent, that pricing and cancellation terms are clearly stated, and that the platform operates in your state. Review regulatory guidance and consult with your primary care provider if you have questions.

Contact Information

For questions about Sprout Health Weight Loss, according to disclosures published on the company’s platform:

• Email: help@joinsprouthealth.com
• Phone: +1 (833) 496-4020
• Hours: According to the company, support is available Monday through Friday, 9 a.m. to 5:30 p.m. Mountain Time.
• Medical Portal: For clinical questions about treatment, side effects, or dosage adjustments, the company provides a medical portal for messaging with the assigned licensed clinician.

External Service Contacts:

According to the company’s terms of service:

• MD Integrations (MDI): support@mdintegrations.com
• Foothills Pharmacy: rx@foothillspharmacy.com
• Promise Pharmacy: info@promisepharmacy.com

Final Perspective: Matching Expectations to Reality for 2026

The search for best peptides for weight loss reflects genuine interest in medically supervised weight management options as 2026 approaches. GLP-1 medications have demonstrated significant weight loss outcomes in clinical trials of FDA-approved branded products, and telehealth platforms have emerged to provide access to compounded versions of these medications at various price points.

What This Industry Analysis Framework Examines:

For individuals evaluating GLP-1 telehealth options, the factors examined in this analysis include:

Pricing transparency: Whether platforms clearly disclose costs, what’s included, and cancellation terms.

Provider model clarity: Whether the three-entity separation (platform, providers, pharmacy) is clearly explained.

Disclosure quality: Whether platforms distinguish between FDA-approved branded medications and compounded formulations.

Format accessibility: What medication formats are available and how the evaluation process works.

Based on publicly available disclosures, Sprout Health represents one platform operating in this category that provides detailed information across these factors.

Considerations for Anyone Evaluating GLP-1 Telehealth Access:

Compounded medications are not FDA-approved: Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed.

Prescription is not guaranteed: Independent clinicians determine appropriateness based on individual health factors.

Results vary significantly: Clinical trial results for branded medications do not predict individual outcomes with compounded versions.

Ongoing cost commitment: Benefits typically require sustained use over months, representing significant financial investment.

Regulatory landscape: The compounded GLP-1 telehealth industry has been under increased regulatory scrutiny. Consumers should verify that any platform they consider maintains clear, accurate disclosures.

Regulatory Context:

The compounded GLP-1 telehealth industry has experienced increased FDA scrutiny in recent years, particularly regarding marketing claims that could mislead consumers about the nature of compounded versus FDA-approved medications. Consumers should review the most current information about any platform’s disclosures and verify that claims align with regulatory guidance before proceeding with GLP-1 programs.

Disclaimers

Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Compounded GLP-1 medications require evaluation by a licensed clinician. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any GLP-1 medication. Do not change, adjust, or discontinue any medications without your physician’s guidance.

Compounded Medication Notice: Compounded semaglutide and tirzepatide are prescription medications prepared by licensed pharmacies based on individual prescriptions. According to FDA guidance, compounded medications are not FDA-approved as finished products. The FDA does not review them for safety, effectiveness, or quality before they are marketed. They are prepared using active pharmaceutical ingredients under federal and state compounding rules based on prescriptions from licensed clinicians.

Results May Vary: Individual results vary based on factors including age, baseline weight, adherence to treatment, lifestyle modifications, and other individual variables. Clinical trial results cited in this article reflect outcomes from studies of FDA-approved branded medications under controlled conditions and do not predict individual outcomes with compounded formulations.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented.

Pricing Disclaimer: All prices, subscription terms, and promotional offers mentioned were based on publicly available platform disclosures as of December 2025 but are subject to change. Always verify current terms directly with the platform.

Copyright © 2025. All rights reserved. This article was published December 2025 and reflects information current as of that date.

CONTACT: Email: help@joinsprouthealth.com
Phone: +1 (833) 496-4020

Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants




Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants

Mexico: The New Hub for US Hair Transplants

Tijuana, BC, Dec. 26, 2025 (GLOBE NEWSWIRE) — Capilea Mexico, a leading hair restoration clinic network in Latin America, today unveiled new insights highlighting Mexico’s emergence as a top destination for US patients seeking hair transplants. The findings point to a growing trend in medical tourism, driven by geographic proximity, lower procedure costs, and increasing trust in Mexico’s advanced hair restoration clinics.

Dr. Héctor Treviño – Medical Director of Capilea Mexico

In recent years, medical tourism has seen a significant rise, particularly in the field of hair transplants. Mexico has emerged as a leading destination for US residents seeking high-quality and affordable hair restoration services. This shift is driven by several key factors that position Mexico as a compelling alternative to domestic options and traditional international destinations like Turkey.

According to recent analyses, Mexico’s strategic location and competitive pricing have solidified its position as a top choice for American patients. The geographic proximity of Mexico offers ease of travel and reduced travel time compared to more distant options, making it an attractive choice for those seeking convenience.

Cost-effectiveness is another major advantage. Mexican clinics offer significantly lower prices for high-quality procedures compared to the US, without compromising on results. This affordability, combined with advanced techniques and skilled specialists, ensures that patients receive exceptional care.

While Turkey continues to attract a significant number of European clients, Mexico has rapidly gained traction among Americans. This trend highlights Mexico’s specific advantage for the US market, offering a superior solution for residents who might be weighing options like flying to Turkey versus driving to Mexico.

Among the leading institutions, Capilea stands out for its exceptional patient care and innovative techniques. Other highly reputable clinics such as Nader Medical and Dr. Angelina Vargas also contribute to Mexico’s growing reputation as a hair transplant hub.

“Mexico’s emergence as a premier destination for hair transplants is a testament to our commitment to quality and patient satisfaction,” says Dr. Héctor Treviño, Medical Director of Capilea.

Insights from US search trends related to “Turkey hair transplant” indicate a growing interest in alternative destinations. Mexico offers a compelling solution for US residents, providing high-quality care closer to home.

As Mexico continues to establish itself as a leader in the hair transplant industry, potential patients are encouraged to explore the top clinics listed for more information. This development not only restores hair but also confidence, offering world-class solutions with a personal touch.

male patient before and after

About Capilea Mexico

Capilea is a premier hair restoration medical center with over 25 years of experience, operating state-of-the-art clinics across Latin America and Spain. The center is renowned for its expertise in advanced FUE hair transplant procedures, as well as PRP therapy and specialized hair loss treatments. Headquartered in Mexico, Capilea runs modern facilities in Monterrey, Tijuana, and Mexico City. Led by distinguished specialists—Dr. Héctor Treviño, Dr. Carlos Rodríguez, and Dr. Benjamín Pérez—Capilea has successfully treated over 11,550 hair graft patients, restoring more than 52,120,000 strands of hair for both domestic and international clients. Its team of certified professionals delivers comprehensive, premium-quality care using the latest advances in technology. With a growing footprint throughout Latin America and now Spain, Capilea remains dedicated to restoring not just hair, but also patient confidence, providing world-class hair restoration solutions with a personal touch. 

Press inquiries

Capilea Mexico
https://capileamexico.com/en/
Dr. Héctor Treviño
admin@capileamexico.com
NewCity Medical Plaza
P.º del Centenario 9580-Piso 2106, Zona Urbana Rio Tijuana

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations




Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare & Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.

On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers scheduled to become effective on January 1, 2026. The LCDs, adopted under an earlier Medicare 2026 Skin Substitute Update, set which skin substitute products would be eligible for Medicare coverage beginning in 2026. While Celularity’s Biovance® and Biovance 3L remained eligible for Medicare coverage under the now-withdrawn LCDs, Medicare coverage was eliminated for 158 skin substitute products sold by other companies. Unaffected by CMS’ recent action is its new payment policy that effective January 1, 2026, all skin substitute applications furnished in physician office settings and hospital outpatient department settings will be paid at a flat rate of $127.28 per square centimeter.

Commenting on the recent change, Dr. Hariri said, “We have amassed substantial real-world evidence, or RWE, from multiple studies showing how our Biovance® Human Amniotic Membrane Allograft works in actual clinical practice for wound healing, demonstrating its effectiveness in diverse, real-life diverse patient populations patients with chronic wounds. RWE from large observational studies published in the peer-reviewed journal WOUNDS and elsewhere show Biovance® effectively treats chronic wounds, even in patients with multiple health issues. Other RWE shows reduced steroid use in about half of patients treated with Biovance®, which evidence indicates helps decrease pro-inflammatory factors and increase anti-inflammatory ones, guiding the body’s natural healing.”

Dr. Hariri noted that CMS’ 2026 Medicare payment policy setting skin substitute reimbursement at a flat $127.28 per square centimeter remains in effect despite it withdrawing the LCDs. “Biovance® has been supported by a highly efficient, proven scalable manufacturing process since its commercial launch in April 2014, which today allows us to operate comfortably under the new Medicare reimbursement for skin substitute products,” he said. “Our sustained investment in advanced infrastructure includes a world-class GMP/GTP manufacturing facility located in Florham Park, New Jersey, where today we manufacture a range of commercial advanced biomaterial products and investigational cell therapy products, including both Celularity branded products and contract manufactured products for third parties. Consistent with our emphasis on real-world evidence gained from actual clinical use of our products, we have integrated an ‘Industry 5.0’ approach into our manufacturing operations, introducing digitization and AI and building adaptable and robust value chains and production systems,” Dr. Hariri said.

About Celularity

Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.

Forward Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) Celularity’s ability to execute its strategic priorities, including leveraging its placental-derived platform and aligning its operations and organizational focus with those priorities; (ii) Celularity’s plans to emphasize applications related to longevity and age-related disease; and (iii) the anticipated impact and benefits of the financing transactions on Celularity’s business and strategic flexibility. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Carlos Ramirez

Senior Vice President, Celularity Inc.

Carlos.ramirez@celularity.com

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources




Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia and Roosevelt dated December 4, 2024, pursuant to the terms of the agreement. The agreement provided for a proposed business combination transaction between the two companies.

“In light of these circumstances, Arcadia will resume the process of evaluating strategic alternatives in order to create value for our shareholders.” said T.J. Schaefer, CEO of Arcadia.

Schaefer continued, “Over the last two-and-a-half years, we have streamlined our operations, significantly reduced our operating expenses and grown the Zola^® coconut water brand while avoiding the use of long-term debt. We continue to own approximately 2.7 million shares of Above Food Ingredients Inc. common stock and believe we are entitled to additional consideration and compensation relating to our May 2024 sale of GoodWheat^TM. We believe these assets, along with our Nasdaq public listing and our Zola business, should make Arcadia an attractive candidate for a merger or other strategic transaction.”

About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets, or future developments or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to statements concerning the following matters: the company’s anticipated financial position, cash needs and ability to continue operations; the company’s beliefs concerning its ability to pursue and enter into alternative strategic transactions and its attractiveness as a candidate for a strategic transaction; the company’s beliefs concerning its entitlement to additional shares of common stock of Above Foods Ingredients Inc. (“ABVE”) and concerning principal and interest payments owed by Above Foods Corp.; and the company’s beliefs concerning the availability of adequate funding to support the company’s future operations from available cash resources, revenues from future sales of products, proceeds from sales of assets including shares of ABVE that it holds (if such shares may be sold pursuant to Rule 144 or otherwise), sale of equity or debt securities, or other transactions. Forward-looking statements concerning anticipated future activities assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. Arcadia will require additional funding in the near future to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings. Any sale of additional equity securities could result in material dilution to company stockholders. If the company is not able to secure adequate additional funding, it could be required to reduce or suspend activities, liquidate assets, or initiate dissolution and liquidation or bankruptcy proceedings. In the event of such proceedings, Arcadia’s creditors would have first claim on the value of the company’s assets which, other than remaining cash, would most likely be liquidated in one or more transactions or a bankruptcy sale, and the common stock of Arcadia likely would have little or no value. Any of these actions would have a material adverse effect on its business, results of operations and financial condition. Forward-looking statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause the company’s actual results to be materially different from the results anticipated by such forward-looking statements. Undue reliance should not be placed on any forward-looking statements. Risks and uncertainties relating to the company’s business and future prospects also include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission (SEC) from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, quarterly reports on Form 10-Q filed with the SEC during the 2025 year, the registration statement on Form S-4 initially filed with the SEC on February 14, 2025 and amended July 31, 2025, and other filings that the company makes with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Further, any forward-looking statement speaks only as of the date as of which it was made, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update forward-looking statements or to reflect events or circumstances arising after the date of this press release.

Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com

IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital




IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital

Louvain-La-Neuve, Belgium, December 26, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Catholic University of Korea, Seoul St. Mary’s Hospital, one of the largest hospital in South Korea, for a Proteus^®PLUS¹ solution to be installed in Seoul.

The contract includes the equipment of a Proteus^®PLUS solution with three gantry-room as well as a multi-year service contract. The system will also include DynamicARC^®2 beam delivery capabilities, once this feature has received regulatory clearance.

The Seoul St. Mary’s Hospital plans to begin patient treatments by the end of 2029. Upon full completion, the center will have eight floors, including underground levels, and a total area of 37,851 square meters.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are pleased to partner with Seoul St. Mary’s Hospital to bring the latest proton therapy technology in South Korea, expanding the number of centers in the country that benefit from IBA’s proton therapy solutions. This contract highlights the relevance of our offering in markets where demand for this cutting-edge treatment modality is strongly increasing. We look forward to working with the expert medical team of Seoul St. Mary’s to make this technology more accessible to patients.”

LEE Ji Youl, MD, PhD, President of Seoul St. Mary’s Hospital, added: “We are pleased to have signed this contract with IBA, the world leader in proton therapy technology, for the introduction of cutting-edge latest-generation equipment. The construction of the center is the final step in completing the Seoul St. Mary’s Hospital complex. Our hospital will provide world-best treatment not only in the field of blood cancers, for which it has earned a global reputation, but also in the treatment of solid tumors.”

The typical end-user price for a three-room Proteus^®PLUS system with a multi-year maintenance contract ranges between € 80 and 100 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

About Seoul St Mary’s Hospital

Seoul St. Mary’s Hospital is one of Korea’s top academic hospitals and the flagship institution of the Catholic Medical Center. It provides comprehensive care across 45 departments and 27 specialized centers, including the Cardio-Cerebro-Vascular Hospital, Catholic Hematology Hospital, and Comprehensive Cancer Hospital. With pioneering achievements such as Korea’s first kidney and bone marrow transplants and Korea’s first artificial cornea transplant, the hospital provides world-class care. Trusted by both domestic and international patients, Seoul St. Mary’s Hospital has treated over 30,000 international patients from more than 100 countries. The hospital continues to enhance the quality of its services and has trained more than 900 international physicians through its fellowship programs.

For further information, please contact:

¹ Proteus^®PLUS is a brand name of Proteus^®235.

² DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under development phase.

Attachment

• 251226-IBA-ProteusPLUS-Korea-EN

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency




XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated December 22, 2025, notifying the Company that based on XTL’s closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

The Nasdaq notification letter does not result in the immediate delisting of the Company’s American Depositary Shares (“ADSs”), and the ADSs will continue to trade uninterrupted under the symbol “XTLB”.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 22, 2026, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide XTL with written confirmation of compliance and this matter will be closed.

In the event the Company does not regain compliance, XTL may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If XTL meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

XTL is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirements. Although XTL will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.

About XTL Biopharmaceuticals Ltd.

XTL is an IP portfolio company.  XTL holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease. The Social Proxy is a web data AI company, developing and powering a unique ethical, IP based, proxy data extraction platform for AI and BI applications at scale.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; and (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: info@xtlbio.com
www.xtlbio.com

LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information




LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information

A summary of the current discussions in consumer health and wellness on the topic of LULUTOX Detox Tea

New York City, NY, Dec. 24, 2025 (GLOBE NEWSWIRE) —  With the ongoing popularity of digestive wellness and daily detox in the popular health and lifestyle discourse, the consumer-facing media has begun to take a closer look at how the topic of herbal supplements is framed, regulated, and interpreted by the general public. In this respect, LULUTOX Detox Tea has declared a modification of its official site, which will help to present a more definite picture of its caffeine-free herbal tea supplement and its purpose as a component of a general wellness program.
Visit Now Official Site

The update of the site is in the context of the ongoing consumer interest in the products that are placed in the digestive balance and internal cleansing. Instead of launching a new formulation or product line, the update is aimed at the availability of information, ingredient disclosure, and use recommendations to people who want to learn more about non-prescription herbal supplements.

Broadening: Digestive Health and Social Welfare regarding the Detox Practices

Within the last few years, the issue of digestive health acquired the leading position in the list of the activity of the wellness discussion because of lifestyle changes, diet, stress, and the increased popularity of gut-related disorders, such as bloating and irregular digestion. As a result, many solutions such as altering diet and probiotics and herbal teas are researched by a large population to get them more at ease within their digestive system.

LULUTOX Detox Tea Explore It To Know More

The detox teas, specifically, are in a specialized niche in this landscape. Historically linked with herbal traditions, these teas are commonly placed as mild, routine-based supplements instead of intensive cleansing protocols. The role of consumer reporting in 2025 is likely to focus more on the need to make a difference between the traditional wellness products and medical interventions as the level of scrutiny of the health claims by the population is expected to increase.

LULUTOX Detox Tea is mentioned in the context of this general discussion as a caffeine-free herbal tea supplement that is to be used on a daily basis. Consumer coverage does not define the product as a medical treatment, therapeutic solution, or a replacement of professional healthcare.

The Web Site Revision and Its Object

The updated LULUTOX site, according to publicly available information, is to display more structured and accessible information on the formulation of the product, its preparation, and overall usage. The update is an indication of a wider trend in the supplement industry towards more direct communication and consumer education.

Instead of emphasizing the use of promotional messages, the site describes the fundamental product features, such as its herbal tea form, caffeine-free make-up, and the ability to prepare it either hot or cold. This kind of information enables consumers to make personal decisions about the product better informed on what the product is and what it is not.

The focus on transparency is in line with the changing consumer expectations. Consumers are also demanding more transparency regarding the use of supplements especially in the area of detox and digestion where falsehoods can be so easily created.

The interpretation of LULUTOX Detox Tea as Dietary Supplement

LULUTOX Detox Tea is defined as a nutritional supplement that is provided in the shape of herbal tea bags. Like all dietary supplements in the United States, it functions under a different regulatory framework as pharmaceuticals. Dietary supplements are not authorized to diagnose, treat, cure or prevent disease and are controlled based on labeling accuracy and safety standards and not based on pre-market efficacy.

Now Time to Order the LULUTOX Detox Tea and Save Big

Articles about LULUTOX focusing on consumers always recognize this difference. The product is presented as a wellness supplement that should be used to supplement daily activities, not a medical fix to digestive disorders or system detoxification.

This framing is especially significant in the detox category, where words may be interpreted to suggest a physiological cleansing that is not already done by the body. Neutral reporting does not imply such implications, as it is directed towards general wellness context.

Ingredient Disclosure and Traditional Use Context

The publicly accessible accounts of LULUTOX Detox Tea mention a combination of herbs, which are traditionally linked to the comfort of the digestive system and the daily well-being. Although individual herbs might have a history of traditional use, consumer coverage observes that traditional use is not similar to clinical validation.

The new site includes ingredient information to enable the consumers to see the formulation on their own. The strategy is conducive to making informed choices and is consistent with the larger consumer education campaigns that make people aware of what they are eating.

Notably, neutral reporting does not claim that certain ingredients have certain guaranteed effects. The studies on herbs tend to be context-dependent, and the findings of the controlled studies or traditional use might not directly apply to the commercial use of supplements.

Standards and Quality of Manufacturing

LULUTOX Detox Tea is said to be produced in the plants that comply with the general quality and safety standards that are used in relation to dietary supplements. Although adherence to manufacturing standards is a regulatory necessity, consumer coverage stresses the point that adherence to manufacturing standards does not mean clinical efficacy.

The reference to manufacturing standards is mostly used to assure consumers that there are minimum regulatory requirements that are satisfied. It is not a recommendation of results or performance.

Visit the Official Website

With the rise in consumer awareness, there is a rise in the demand to know more about the production of supplements, particularly their origin. This is a wider trend of accountability and transparency in the wellness industry, which is reflected in the addition of manufacturing information.

Public Scrutiny and Consumer Feedback

Alongside the official product descriptions, the online views and third-party commentary are becoming more and more influential in the way the supplements are perceived by the mass audience. Articles that are consumer-oriented and analyze LULUTOX Detox Tea mention that there are mixed views, which represent a variety of personal experiences.

This coverage usually warns the reader not to take anecdotal views as conclusive. The dietary supplements may have a wide range of experiences based on the individual physiology, diet, hydration and lifestyle.

The use of neutral reporting makes readers perceive feedback as personal narrative and not clinical evidence. This moderation strategy can avoid overgeneralization and facilitate realistic expectations.

Gastrointestinal Health, Cleanse, and Myths

The necessity to dispel the widespread misconceptions is one of the themes that can be repeated in consumer education on detox products. Health experts often mention that the human body already has its own efficient detoxification mechanisms, which are the liver, the kidneys and the digestive tract.

In this regard, the products like LULUTOX Detox Tea are discussed as wellness facilitators, not physiological ones. Consumer coverage is the fact that these products are not aimed to replace healthy food, drink, or medical treatment.

This explanation is especially important considering the popularity of detox language in marketing. The neutral press coverage aims at placing such language in context and strengthening evidence-based knowledge.

The Uses of Caffeine-Free Herbal Teas in the Daily Routines

Herbal teas with no caffeine have a niche in the everyday wellness routine. They are used by many people as part of a regimen to hydrate, relax or to aid in digestion. Consumer observes that lack of caffeine can be of value to those who are sensitive to stimulant or those who want to use it in the evening.

The LULUTOX Detox Tea is presented within this category where its main characteristic is in the format of tea instead of the use of capsules or powder. This difference is important to consumers who like conventional ways of making tea or those who have a connotation of tea preparation as a daily habit and moderation.

Customer Warranties and Customer Guarantees

The information that is publicly available points out that LULUTOX Detox Tea provides a satisfaction guarantee to the customers who have newly joined the company. Consumer coverage relates such policies to normal commercial practices, but not to a product performance indicator.

Exclusive offers, visit the official LULUTOX website

The issue of guarantees is addressed with respect to consumer protection, and people have an opportunity to make a wise choice in terms of buying goods. The neutral reporting does not interpret the guarantees as effectiveness.

The Regulatory Environment and Accountable Communication

The food supplement industry is regulated with an aim of guaranteeing safety and accurate labeling. Nevertheless, the supplements do not have to prove their effectiveness before entering the market. Commercial coverage that mentions LULUTOX Detox Tea indicates increased awareness of the difference in society.

Accountable communication, especially in the press releases, involves the use of responsible language that does not suggest health benefits. The update on the LULUTOX site seems to be consistent with this strategy, as it is descriptive and does not involve outcome-related statements.

Expansive Wellness Communication Implications

The focus on the update of the LULUTOX Detox Tea website is a part of a widespread tendency of wellness brands to address the consumer. More and more, it is being acknowledged that trust can be established by being clear, restrained and respectful of consumer intelligence instead of promoting aggressively.

The role of neutral press coverage in this ecosystem is to put products into context in bigger trends as opposed to trending up marketing stories. By so doing, it will help in making informed civic dialogue regarding wellness options.

Frequently Asked Questions

1- What is LULUTOX Detox Tea, by consumer coverage?

According to consumer-based reporting, LULUTOX Detox Tea is a herbal-based caffeine-free tea supplement that falls under the category of digestive wellness and daily detox products. It is also introduced as a non-prescription commodity to be used in general wellness as opposed to a medical treatment or therapeutic intervention.

2- Does the press release purport that LULUTOX Detox Tea is a medical detoxification?

No. The press release is not arguing that LULUTOX Detox Tea is medically detoxifying the body and it is substituting the natural mechanism of body detoxification. It has a clear difference between wellness oriented herbal supplements and clinical or medical detox treatments and has highlighted the major role played by body organs like liver and kidneys in undertaking the various body functions of detox.

3- Why has LULUTOX Detox Tea appeared in the eyes of consumers in 2025?

The LULUTOX Detox Tea is among those that have been mentioned in the consumer conversations with the current social concerns in relation to the digestive health, bloating prevention, and wellness routine. Its reference indicates a wider interest in herbal teas and supplements as opposed to approval or clinical support.

4- Do the ingredients of LULUTOX Detox Tea have scientifically proven results to achieve certain outcomes?

The press release does not insist that the ingredients or formulation has been scientifically tested to provide certain digestive or detox effects. Although the history of some herbs has been a record of tradition, consumer coverage reminds that the research of an ingredient in its traditional form or a single ingredient does not necessarily yield the same results when used as a commercial supplement.

5- Who is advised to consult a professional with regards to the use of detox tea supplements?

People who have underlying medical issues, take any prescription drugs, are pregnant or lactating or have any health related issues are advised to first seek the advice of a qualified health care specialist before taking any dietary supplement, herbal detox teas. This is an indication of overall best-practice guidelines within the supplement industry.

Conclusion

The new look of the LULUTOX Detox Tea site and the following news on a consumer oriented media underline that there has been continuous activity in the wellness industry to enhance transparency and communication. LULUTOX Detox Tea is being marketed as a caffeine-free herbal tea supplement, designed to support general digestive and wellness without making any medical claims or guaranteeing results.

With the product placed in the wider contexts of digestive health, detox myths, regulatory framework, and customer education, coverage focuses on education rather than advertising. With the growing popularity of wellness supplements among the general population, this form of balanced reporting is the only way to help people maneuver in an ever-growing marketplace.

Company: LULUTOX Detox Tea 

Email: support@lulutox.com

Phone: +1(888) 828-8953

Website: https://shop.lulutox.com/

Attachment

• Lulutox

CONTACT: Company: LULUTOX Detox Tea 

Email: support@lulutox.com

Phone: +1(888) 828-8953

Website: https://shop.lulutox.com/

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support




Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) — This holiday season, addiction experts at Desert Hope Treatment Center are encouraging individuals in recovery to stay connected to support, as research shows drug and alcohol relapse rates spike during the holidays. Factors such as heightened emotional stress, disrupted routines, social pressures, and isolation contribute to an increased risk of relapse, especially when early warning signs are overlooked.

Clinicians at Desert Hope note that relapse often begins mentally before any physical return to substance use occurs. Recognizing the warning signs early and reaching out for help can be critical for protecting recovery.

Common warning signs include:

• Increased cravings or persistent thoughts about using
• Romanticizing past substance use or minimizing its consequences
• Pulling away from support systems, meetings or loved ones
• Increased anxiety, depression, irritability or emotional numbness

“The holidays can intensify emotional stress, even for people who have been stable in recovery for some time,” said Ariann Chelli, Clinical Director, Desert Hope Treatment Center. “Asking for help is not failure. Addiction is a chronic, progressive disease. It’s important to reach out before a relapse occurs. For some, that may mean leaning on additional support. For others that may mean returning to treatment for a period of time.”

Clinicians at the Nevada drug rehab stress that the risk of relapse increases when individuals delay seeking help or minimize early warning signs. Many notice mental and emotional shifts weeks before a relapse but wait until reaching a crisis point to reach out.

Desert Hope Treatment Center reminds individuals in recovery, their families, and community members that support is available throughout the holiday season. Alumni of Desert Hope programs are also encouraged to reconnect through the AAC Together app if they feel challenged or need additional support.

“We want people who are struggling to know our doors are always open,” said Chelli.

About Desert Hope Treatment Center
Desert Hope Treatment Center, located in Las Vegas, NV, serves the greater Las Vegas area and individuals nationwide with evidence-based addiction and mental health treatment. We provide a full continuum of inpatient and outpatient services, as well as sober living, for individuals facing substance use and co-occurring mental health disorders. We believe in the power of recovery and are committed to restoring hope, empowering individuals and families, and breaking the stigma of addiction. Our specialized programs, including tailored support for Veterans, offer a strong foundation for lasting recovery that transforms lives. Desert Hope Treatment Center is part of American Addiction Centers, a national leader in addiction treatment. Learn more at deserthopetreatment.com.

Desert Hope Contacts

Joy Sutton
American Addition Centers
VP of Brand and Communications
jsutton@contactaac.com